Views 691
Citations 0
Clinical Trials Update
October 27, 2015

No Benefit From High 25(OH)D Levels for Postmenopausal Women

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(16):1684. doi:10.1001/jama.2015.13426

High-dose vitamin D supplementation in postmenopausal women without osteoporosis had no clinically beneficial effects on bone mineral density, muscle function, muscle mass, or falls, according to the results of a recent clinical trial (Hansen KE et al. JAMA Intern Med. doi:10.1001/jamainternmed.2015.3874 [published online August 3, 2015]).

The trial compared the effects of placebo, low-dose cholecalciferol, and high-dose cholecalciferol on 1-year changes in total fractional calcium absorption, bone mineral density, sit-to-stand tests, and muscle mass in 230 postmenopausal women (≤75 years; mean age, 61 years) with vitamin D insufficiency (baseline 25[OH]D levels, 14-27 ng/mL). Trial participants were randomly assigned to receive daily and twice-monthly placebo pills; daily 800 IU vitamin D3 (low dose) and twice-monthly yellow placebo pills; or daily white placebo and twice-monthly 50 000 IU vitamin D3 (high dose) pills—which maintained 25(OH) D levels at greater than or equal to 30 ng/mL.

First Page Preview View Large
First page PDF preview
First page PDF preview